메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

XPOVIO® Approved in Hong Kong for Two Additional Indication…

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (R/RDLBCL) and as a combination therapy when used together with bortezomib and dexamethasone (XVd) for MM patients who received at least one prior therapy. - XPOVIO® is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO® i
- 김갑성 기자
- 2025-12-03 17:00
S3 Connected Health Receives Frost & Sullivan's 2025 Global Co…

[ 메디채널 김갑성 기자 ] Recognized for pioneering advancements that redefine medical device connectivity, accelerate home-based care, and deliver transformative value across global healthcare ecosystems. SAN ANTONIO, Dec. 3, 2025 -- Frost & Sullivan is pleased to announce that S3 Connected Health has received the 2025 Global Company of the Year Recognition in the Medical Device Connectivity (MDC) industry for its outstanding achievements in driving technology innovation, advancing care delivery, and enabling seamless connectivity from hospital to home. This recognition highlights the com
- 김갑성 기자
- 2025-12-03 16:00
뉴소프트 메디컬 시스템즈, 2025 북미영상의학회에서 세계 최초 8cm 광역 커버리지 광자…

[ 메디채널 김갑성 기자 ] 시카고 2025년 12월 3일 -- 글로벌 의료 영상 선도 기업인 뉴소프트 메디컬 시스템즈(Neusoft Medical Systems Co., Ltd., 이하 '뉴소프트 메디컬')가 2025 북미영상의학회(Radiological Society of North America, RSNA) 연례 회의에서 포괄적인 지능형 헬스케어 혁신 포트폴리오를 선보인다. 이번 전시의 하이라이트는 세계 최초의 8cm 광역 커버리지 광자 계수(photon-counting) CT인 NeuViz P10의 획기적인 출시다. 이와 함께 다양한 하이엔드 영상 시스템 및 인공지능(AI) 통합 임상 솔루션도 함께 전시된다. 현장 시연에서는 검진, 진단, 치료, 재활 및 연구를 아우르는 전주기 지능형 영상 생태계를 제시하며, 임상 결과 개선을 위한 효율적이고 연결된 경로를 제공한다. 뉴소프트 메디컬 부사장인 장단(Zhang Dan) 국제 비즈니스 센터 총괄은 "이 글로벌 무대에서 탁월한 영상 성능과 지능형 케어를 제공하는 첨단 기술을 선보이게 되어 영광"이라면서 "혁신적인 광자 계수 CT인 Neu
- 김갑성 기자
- 2025-12-03 14:59
World-Leading Microsurgeon Professor J.P. Hong Joins Med…

SINGAPORE, Dec. 3, 2025 -- MediThinQ, a fast-growing innovator in surgical displays and digital 3D microscopy, today announced that world-renowned reconstructive microsurgeon Prof. Joon-pio Hong has joined the company as Chief Medical Officer. His decision marks one of the strongest clinical endorsements to date for MediThinQ's next-generation digital microsurgery platform, SHIYA 20. Prof. Hong is President of the World Society for Reconstructive Microsurgery, Professor at Asan Medical Center in Korea, and Adjunct Professor at Georgetown University in the United States. Widely
- 김갑성 기자
- 2025-12-03 09:00
Celltrion announces U.S. FDA approval of 300mg strength of OM…

FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases OMLYCLO® (omalizumab-igec) is the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab); The FDA previously approved OMLYCLO® 75 mg/0.5 mL and 150 mg/mL in a single-dose prefilled syringe for subcutaneous injection in March 2025 INCHEON, South Korea, Dec. 3, 2025 -- Celltrion, Inc. today ann
- 김갑성 기자
- 2025-12-03 08:43
어코드 헬스케어, 두 번째 골다공증 바이오시밀러 제품인 데노수맙 출시

∇ 이 의약품은 추가적인 모니터링 대상이다. 모니터링 목적은 새로운 안전성 정보를 신속하게 파악하는 것이다. 런던, 2025년 12월 3일 -- 어코드 헬스케어(Accord Healthcare)가 오늘 2025년 11월 27일 기존 의약품의 특허 만료 시점에 맞춰 진행해 오던 대로, 프롤리아(Prolia®, 암젠(Amgen) 제조)의 데노수맙(Denosumab) 계열 바이오시밀러 제품인 오스비르티(Osvyrti)와 엑스제바(Xgeva®, 암젠 제조)의 데노수맙 계열 바이오시밀러 제품인 주베렉(Jubereq)를 출시한다고 발표했다. 두 가지 의약품은 모두 기존 제품인 프롤리아(암젠 제조)와의 극도로 높은 유사성을 입증한 임상 시험 데이터를 바탕으로 올해 9월에 유럽의약품청(European Medicines Agency, EMA)의 승인을 받았다. 어코드 헬스케어가 데노수맙 계열의 골다공증 바이오시밀러 제품을 출시한 것은 이번이 두 번째이며, 이로써 저렴한 가격에 고품질 의약품을 더 많은 환자에게 보급하려는 어코드 헬스케어의 헌신이 다시 한번 빛을 발하게 되었다. 골다공증 분야의 의
- 김갑성 기자
- 2025-12-03 06:45
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIO…

- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary studies - Key Takeaways Findings from three NIA-funded ancillary studies to the U.S. POINTER trial described beneficial effects as measured by brain imaging, sleep health, and blood pressure regulation. The U.S. POINTER recipe, a 2-year multicomponent healthy lifestyle intervention with regular structured support, improved blood pressure regulation of blood flow to the brain, reduced sleep apnea respiratory events, and increased cognitive resilience for adults with certain Alzhe
- 김갑성 기자
- 2025-12-03 03:00
Natural Field Releases "Ashwagandha White Paper" and La…

HANGZHOU, China, Dec. 3, 2025 -- Against the backdrop of the accelerated upgrading of the global functional nutrition industry, technology-driven ingredient enterprises are increasingly emerging as the core force of the industrial chain. In November 2025, the FTA (Food Research Exchange Super Ingredients Conference) was successfully held in Hangzhou, gathering renowned enterprises from the fields of functional foods, nutritional ingredients, and innovative technologies to jointly showcase the latest industry trends. Among them, Natural Field, a company with years of experience in plant active
- 김갑성 기자
- 2025-12-03 00:00
TraceLink Announces 2025 Corporate Grant Recipients Drivin…

Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose SummaryTraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the U.S., India, and Spain and providing volunteer opportunities for employees. Built on its mission to enhance health, safety, and the greater good by giving back, the program empowers nonprofits creating healthier, more equitable communities worldwide. BOSTON, Dec. 2, 2025 -- TraceLink, the largest end-to-end digital network platfo
- 김갑성 기자
- 2025-12-02 23:00
Lunit to Highlight New AI Evidence in Cancer Screening and B…

Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 studies at the Radiological Society of North America (RSNA) 2025 Annual Meeting. Spanning screening mammography, digital breast tomosynthesis (DBT), breast density science, and risk modeling, this year's program represents one of the company's most extensive evidence portfolios to date. Lunit will exhib
- 김갑성 기자
- 2025-12-02 22:10

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분